Ocumension Therapeutics
HKEX:1477
Intrinsic Value
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. [ Read More ]
The intrinsic value of one
Ocumension Therapeutics
stock under the Base Case scenario is
7.46
HKD.
Compared to the current market price of 6.98 HKD,
Ocumension Therapeutics
is
Undervalued by 6%.
Ocumension Therapeutics's market capitalization is 4.8B HKD.
Ocumension Therapeutics stock price is 6.98 HKD.
Ocumension Therapeutics stock price (6.98 HKD) is 6% less than its Intrinsic Value (7.46 HKD).
Ocumension Therapeutics stock price (6.98 HKD) is 25% less than its DCF Value (9.28 HKD). Open DCF Valuation
Ocumension Therapeutics stock (5.63 HKD) is 19% less than its price (6.98 HKD). Open Relative Valuation
Ocumension Therapeutics has upside potential of 23% compared to the average analyst price target.
Open Wall St Estimates
Ocumension Therapeutics's Revenue has grown by an exceptional 55% over the past 12 months.
Ocumension Therapeutics's ROE (Return on Equity) for the past 12 months is negative and is equal to -13%.
Ocumension Therapeutics has negative Operating Income for the last twelve months.
Ocumension Therapeutics has negative Net Income for the last twelve months.
Ocumension Therapeutics's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -22%.
Ocumension Therapeutics has positive Gross Profit for the last twelve months.
Ocumension Therapeutics's Revenue is forecast to grow at a rate of 83% per year over the next 3 years.
Ocumension Therapeutics has negative Free Cash Flow for the last twelve months.
Ocumension Therapeutics has negative three-year average ROE (Return on Equity): -13%. The company is not efficient at transforming stockholders' equity into net income.
Ocumension Therapeutics's short-term assets (1B CNY) exceed its short-term liabilties (315m CNY).
Ocumension Therapeutics's D/E (Debt to Equity) is very low and is equal to 0.04.
Ocumension Therapeutics has negative three-year average ROIC (Return on Invested Capital): -29%. The company is not efficient at using invested capital to generate operating income.
Ocumension Therapeutics's long-term assets (3B CNY) exceed its long-term liabilties (351m CNY).
Ocumension Therapeutics has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (126m CNY).
Ocumension Therapeutics's Altman Z-Score is very high and is equal to 5.27.
Ocumension Therapeutics doesn't generate enough operating income (-406m CNY) to safely cover interest payments on its debt (1m CNY).
Valuation Backtest
Ocumension Therapeutics
Run backtest to discover the historical profit from buying and selling
Ocumension Therapeutics
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ocumension Therapeutics
Balance Sheet Decomposition
Ocumension Therapeutics
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 119.4m |
| Other Current Assets | 32.5m |
| Non-Current Assets | 2.1B |
| Long-Term Investments | 364.1m |
| PP&E | 467.7m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 93.4m |
| Current Liabilities | 315.3m |
| Accounts Payable | 207.8m |
| Accrued Liabilities | 25.3m |
| Short-Term Debt | 120m |
| Other Current Liabilities | -37.8m |
| Non-Current Liabilities | 35.7m |
| Long-Term Debt | 5.7m |
| Other Non-Current Liabilities | 30.1m |
Earnings Waterfall
Ocumension Therapeutics
|
Revenue
|
246.4m
CNY
|
|
Cost of Revenue
|
-102m
CNY
|
|
Gross Profit
|
144.4m
CNY
|
|
Operating Expenses
|
-549.9m
CNY
|
|
Operating Income
|
-405.5m
CNY
|
|
Other Expenses
|
25.7m
CNY
|
|
Net Income
|
-379.8m
CNY
|
Free Cash Flow Analysis
Ocumension Therapeutics
Profitability Score
Profitability Due Diligence
Ocumension Therapeutics's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Ocumension Therapeutics's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ocumension Therapeutics's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Ocumension Therapeutics's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ocumension Therapeutics
According to Wall Street analysts, the average 1-year price target for
Ocumension Therapeutics
is 8.59 HKD
with a low forecast of 6.06 HKD and a high forecast of 12.86 HKD.
Shareholder Return
Price
Ocumension Therapeutics
| Average Annual Return | -35.18% |
| Standard Deviation of Annual Returns | 10.69% |
| Max Drawdown | -87% |
| Market Capitalization | 4.8B HKD |
| Shares Outstanding | 673 895 114 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Ocumension Therapeutics
Country
Industry
Market Cap
Dividend Yield
Description
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Ocumension Therapeutics
stock under the Base Case scenario is
7.46
HKD.
Compared to the current market price of 6.98 HKD,
Ocumension Therapeutics
is
Undervalued by 6%.
You don't have any saved screeners yet
